300158 振东制药
已收盘 10-30 15:00:00
资讯
新帖
简况
外企背景总裁不到一年“闪辞”，知名药企90后“药二代”全面接掌！
红星资本局 · 10-28 17:13
外企背景总裁不到一年“闪辞”，知名药企90后“药二代”全面接掌！
振东制药(300158)9月30日股东户数4.41万户，较上期增加5.3%
证券之星 · 10-27
振东制药(300158)9月30日股东户数4.41万户，较上期增加5.3%
振东制药连亏4年3季总股本14.5%质押 前海人寿持股
中金财经 · 10-27
振东制药连亏4年3季总股本14.5%质押 前海人寿持股
股市必读：振东制药新发布《第六届董事会第十七次会议决议公告》
证券之星 · 10-27
股市必读：振东制药新发布《第六届董事会第十七次会议决议公告》
图解振东制药三季报：第三季度单季净利润同比下降740.54%
证券之星 · 10-27
图解振东制药三季报：第三季度单季净利润同比下降740.54%
振东制药（300158）披露关于变更收购广东龙创基药业有限公司股权付款节奏暨分步交割安排的议案，10月26日股价下跌0.6%
证券之星 · 10-26
振东制药（300158）披露关于变更收购广东龙创基药业有限公司股权付款节奏暨分步交割安排的议案，10月26日股价下跌0.6%
股市必读：振东制药（300158）10月22日董秘有最新回复
证券之星 · 10-23
股市必读：振东制药（300158）10月22日董秘有最新回复
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
证券之星 · 10-22
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
股市必读：振东制药（300158）10月19日董秘有最新回复
证券之星 · 10-20
股市必读：振东制药（300158）10月19日董秘有最新回复
股市必读：振东制药（300158）10月8日董秘有最新回复
证券之星 · 10-09
股市必读：振东制药（300158）10月8日董秘有最新回复
振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血
证券之星 · 10-08
振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血
振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品
证券之星 · 09-17
振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品
振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主
证券之星 · 09-04
振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主
振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中
证券之星 · 09-02
振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中
股市必读：振东制药（300158）8月27日董秘有最新回复
证券之星 · 08-28
股市必读：振东制药（300158）8月27日董秘有最新回复
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
证券之星 · 08-27
振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中
振东制药2026年中报：战略调整营收承压 研发逆势加码
中国财富通 · 08-26
振东制药2026年中报：战略调整营收承压 研发逆势加码
振东制药上半年同比由盈转亏 前海人寿保险为前十股东
中金财经 · 08-26
振东制药上半年同比由盈转亏 前海人寿保险为前十股东
股市必读：振东制药新发布《2026年半年度报告摘要》
证券之星 · 08-26
股市必读：振东制药新发布《2026年半年度报告摘要》
图解振东制药中报：第二季度单季净利润同比下降1453.38%
证券之星 · 08-26
图解振东制药中报：第二季度单季净利润同比下降1453.38%
加载更多
公司概况
公司名称：
山西振东制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-01-07
主营业务：
山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是中成药、化药。
发行价格：
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":4.62,"timestamp":1793343801000,"preClose":4.67,"halted":0,"volume":8541200,"delay":0,"changeRate":-0.0107,"floatShares":992000000,"shares":992000000,"eps":-0.4977,"marketStatus":"已收盘","change":-0.05,"latestTime":"10-30 15:00:00","open":4.55,"high":4.82,"low":4.52,"amount":39771300,"amplitude":0.0642,"askPrice":4.63,"askSize":274,"bidPrice":4.62,"bidSize":1745,"shortable":0,"etf":0,"ttmEps":-0.4977,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.67,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":5.14,"lowLimit":4.2,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":992303056,"isCdr":false,"pbRate":1.46,"roa":"--","roe":"--","epsLYR":-0.2998,"committee":0.185768,"marketValue":4584000000,"turnoverRate":0.0086,"status":1,"floatMarketCap":4582000000},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2678457686","title":"外企背景总裁不到一年“闪辞”，知名药企90后“药二代”全面接掌！","url":"https://stock-news.laohu8.com/highlight/detail?id=2678457686","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678457686?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:13","pubTimestamp":1793178780,"startTime":"0","endTime":"0","summary":"辞职后，王锐不再担任公司任何职务，其所负责工作已完成交接。红星资本局注意到，王锐是一位有着外企背景的医药经理人，于2025年12月31日被振东制药聘任为总裁，至今任职未满一年。王锐原定任期至第六届董事会届满之日即2027年9月10日止。业绩方面，自2022年以来，振东制药的营收持续下滑，归母净利润一直为负。2025年，该公司中药、化药、其他业务收入均同比下滑，仅非药品收入同比增长17.60%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-10-28/doc-iniwuqvv9440864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000513","BK0188","BK0186","BK0239","BK0187","300158","BK0060","BK0028","300363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678517591","title":"振东制药(300158)9月30日股东户数4.41万户，较上期增加5.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678517591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678517591?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:48","pubTimestamp":1793098136,"startTime":"0","endTime":"0","summary":"证券之星消息，近日振东制药披露，截至2026年9月30日公司股东户数为4.41万户，较6月30日增加2220.0户，增幅为5.3%。在中药行业个股中，振东制药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.24万户。从股价来看，2026年6月30日至2026年9月30日，振东制药区间涨幅为13.02%，在此期间股东户数增加2220.0户，增幅为5.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700035188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678514154","title":"振东制药连亏4年3季总股本14.5%质押 前海人寿持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678514154","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678514154?lang=zh_cn&edition=full","pubTime":"2026-10-27 11:29","pubTimestamp":1793071744,"startTime":"0","endTime":"0","summary":"中国经济网北京10月27日讯 振东制药 昨晚披露的2026年第三季度报告显示，公司前三季度实现营业收入15.33亿元，同比下降30.79%；归属于上市公司股东的净利润-1.72亿元，归属于上市公司股东的扣除非经常性损益的净利润-1.94亿元。 振东制药2026年第三季度报告显示，公司控股股东山西振东健康产业集团有限公司持股数量为302,230,191股，持股比例为30.46%，其中质押股份数量为143,800,000股，占公司总股本比例的14.49%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/27/20261027793212.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/27/20261027793212.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261027/32408696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300158","BK0060","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678111982","title":"股市必读：振东制药新发布《第六届董事会第十七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678111982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678111982?lang=zh_cn&edition=full","pubTime":"2026-10-27 04:10","pubTimestamp":1793045421,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第十七次会议决议公告山西振东制药股份有限公司于2026年10月26日召开第六届董事会第十七次会议，审议通过《2026年第三季度报告》《关于公司向银行申请并购贷款及授信额度并接受关联方担保暨关联交易的议案》《关于变更收购广东龙创基药业有限公司股权付款节奏暨分步交割安排的议案》及《关于聘任总裁的议案》；关联交易事项关联董事回避表决；相关议案已由董事会下设委员会审议通过；会议召集程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700006052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678113959","title":"图解振东制药三季报：第三季度单季净利润同比下降740.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678113959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678113959?lang=zh_cn&edition=full","pubTime":"2026-10-27 02:28","pubTimestamp":1793039324,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2026年三季报显示，前三季度公司主营收入15.33亿元，同比下降30.79%；归母净利润-1.72亿元，同比下降946.41%；扣非净利润-1.94亿元，同比下降38394.63%；其中2026年第三季度，公司单季度主营收入4.36亿元，同比下降42.44%；单季度归母净利润-7963.71万元，同比下降740.54%；单季度扣非净利润-8687.9万元，同比下降1100.45%；负债率25.07%，投资收益352.13万元，财务费用558.49万元，毛利率51.6%。财报数据概要请见下图:本文数据来源于振东制药2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700003487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678194637","title":"振东制药（300158）披露关于变更收购广东龙创基药业有限公司股权付款节奏暨分步交割安排的议案，10月26日股价下跌0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678194637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678194637?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:39","pubTimestamp":1793025553,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘，振东制药报收于4.93元，较前一交易日下跌0.6%，最新总市值为48.92亿元。该股当日开盘4.9元，最高4.99元，最低4.86元，成交额达3639.18万元，换手率为0.74%。公告显示，该议案涉及对广东龙创基药业有限公司股权收购事项的付款节奏调整及分步交割安排。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600037966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677992589","title":"股市必读：振东制药（300158）10月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2677992589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677992589?lang=zh_cn&edition=full","pubTime":"2026-10-23 05:30","pubTimestamp":1792704635,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，振东制药报收于4.94元，下跌2.56%，换手率0.83%，成交量8.24万手，成交额4111.22万元。董秘最新回复投资者： 请介绍一下用乳杆菌二联活菌胶囊的上市进度如何了？格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。当日关注点交易信息汇总：10月22日主力资金净流出0.06万元，游资资金净流入85.85万元、占总成交额2.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300004730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677965301","title":"振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2677965301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677965301?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:48","pubTimestamp":1792673312,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药(300158)10月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请介绍一下用乳杆菌二联活菌胶囊的上市进度如何了？谢谢！振东制药回复：尊敬的投资者您好！格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。药品研发及注册审批周期长、环节多，最终能否顺利获批、获批时间及上市后的市场销售情况均存在不确定性，敬请广大投资者理性投资，注意投资风险。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200039742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676389526","title":"股市必读：振东制药（300158）10月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2676389526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676389526?lang=zh_cn&edition=full","pubTime":"2026-10-20 01:46","pubTimestamp":1792431975,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，振东制药报收于4.97元，下跌1.39%，换手率1.02%，成交量10.1万手，成交额5015.75万元。中药材储备属于动态管理，公司会结合市场供需、原料特性、资金安排等因素适时调整。当日关注点交易信息汇总：10月19日主力资金净流出251.33万元，占总成交额5.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000001945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674002060","title":"股市必读：振东制药（300158）10月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2674002060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674002060?lang=zh_cn&edition=full","pubTime":"2026-10-09 03:15","pubTimestamp":1791486912,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，振东制药报收于5.15元，下跌1.15%，换手率1.2%，成交量11.86万手，成交额6143.89万元。董秘最新回复投资者： 公司复方苦参注射液对克罗恩病有没有抑制作用？复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血。当日关注点交易信息汇总：10月8日主力资金净流入118.81万元，占总成交额1.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","BK0239","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673772080","title":"振东制药：复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血","url":"https://stock-news.laohu8.com/highlight/detail?id=2673772080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673772080?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:48","pubTimestamp":1791463690,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药10月08日在投资者关系平台上答复投资者关心的问题。非常感谢您的提问以及对公司中药研发方向提出的宝贵建议。复方苦参注射液为公司抗肿瘤中药注射剂，用于癌肿疼痛、出血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800031933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967562","title":"振东制药：现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668967562?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:51","pubTimestamp":1789649493,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药09月17日在投资者关系平台上答复投资者关心的问题。公司依托中药材资源优势，持续布局中药业务，现有复方苦参注射液、西黄丸、独一味颗粒、大山楂丸等成熟中药产品。关于在研新药核准进展，如后续达到信息披露标准，公司将严格按照监管要求及时对外披露。药品研发及注册审批周期长、环节多，最终能否顺利获批、获批时间及上市后的市场销售情况均存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700034408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","300158","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733426","title":"振东制药：复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664733426?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:51","pubTimestamp":1788526274,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药(300158)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：公司去年代理的辉凌制药原研的肠道药物复方匹可硫酸钠颗粒）这药评论说味道好，对肾影响小）！今天去三甲医院做肠胃镜，医生说没这个药（福建），开出药方还是那种很难喝的药！请问你们药品布局这么慢吗？还是有地域限制营销？谢谢！振东制药回复：尊敬的投资者您好！复方匹可硫酸钠颗粒目前购买渠道主要以院边药店为主，也可以通过线上正规渠道购买。公司会持续加快市场布局和院端准入工作。感谢您的支持与关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400039222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681466","title":"振东制药：磷酸芦可替尼乳膏项目相关研发工作正在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681466?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:51","pubTimestamp":1788353501,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：2025年年报披露公司正在研发治疗白癜风的靶向药：磷酸芦可替尼乳膏！公司磷酸芦可替尼乳膏项目相关研发工作正在正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200040565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203126","title":"股市必读：振东制药（300158）8月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662203126?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:34","pubTimestamp":1787873656,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，振东制药报收于5.25元，上涨0.19%，换手率1.61%，成交量15.96万手，成交额8392.42万元。董秘最新回复投资者： 董秘你好：今天从CDE网站了解到，公司重要生物制品：乳酸菌胶囊今天已经出列，祝贺！后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。当日关注点交易信息汇总：8月27日主力资金净流入133.06万元，占总成交额1.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003617","title":"振东制药：格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662003617?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:48","pubTimestamp":1787834906,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药08月27日在投资者关系平台上答复投资者关心的问题。格氏乳杆菌二联活菌胶囊目前药品上市申请审评工作正常推进中。后续如有达到信息披露标准的重大进展，公司将严格按照监管规定及时履行信息披露义务。药品研发及注册审批周期长、环节多，最终能否顺利获批、获批时间及上市后的市场销售情况均存在不确定性，敬请广大投资者理性投资，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792791","title":"振东制药2026年中报：战略调整营收承压 研发逆势加码","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792791","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792791?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:54","pubTimestamp":1787738073,"startTime":"0","endTime":"0","summary":"振东制药于8月25日晚间披露2026年半年度报告。报告期内，中药毛利率49.87%，化药毛利率57.14%，销售费用同比下降19.67%，显示降本增效措施具有一定成效。报告期内，公司研发投入合计1.13亿元，较上年同期增长23.43%。其中，男用米诺地尔泡沫剂已于2026年4月获国家药监局药品审评中心受理上市许可申请；非那雄胺片、二硫化硒洗剂等多款皮科用药处于申报上市阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=3x4TQQfRN7c%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793363","title":"振东制药上半年同比由盈转亏 前海人寿保险为前十股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793363","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793363?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:14","pubTimestamp":1787728442,"startTime":"0","endTime":"0","summary":"中国经济网北京8月26日讯 振东制药(300158.SZ)昨晚发布2026年半年度报告。\r\n\r\n 报告期内，公司营业收入为10.97亿元，同比减少24.74%；归属于上市公司股东的净利润-9272.55万元，上年同期为793.13万元，同比由盈转亏；归属于上市公司股东的扣除非经常性损益的净利润-1.07亿元，上年同期为-817.64万元；经营活动产生的现金流量净额-3.48亿元。\r\n\r\n \r\n\r\n 截止2026年6月30日，前海人寿保险股份有限公司-自有资金为公司第三大股东，持股21699940股，持股比例2.19%。\r\n\r\n \r\n\r\n (责任编辑：孙辰炜)","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/26/20260826827238.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/26/20260826827238.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260826/32347996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0060","BK0186","BK0239","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754601","title":"股市必读：振东制药新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662754601?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:58","pubTimestamp":1787687922,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，振东制药报收于5.31元，上涨4.12%，换手率2.49%，成交量24.67万手，成交额1.29亿元。当日关注点交易信息汇总：8月25日主力资金净流出809.14万元，占总成交额6.27%； 公司公告汇总：振东制药2026年半年度报告披露，营业收入同比下降24.74%，归母净利润为-9272.55万元，同比下降1269.11%； 交易信息汇总资金流向8月25日主力资金净流出809.14万元，占总成交额6.27%；游资资金净流出365.35万元，占总成交额2.83%；散户资金净流入1174.49万元，占总成交额9.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600007630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","300158","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751241","title":"图解振东制药中报：第二季度单季净利润同比下降1453.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751241","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751241?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:10","pubTimestamp":1787685024,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2026年中报显示，上半年度公司主营收入10.97亿元，同比下降24.74%；归母净利润-9272.55万元，同比下降1269.11%；扣非净利润-1.07亿元，同比下降1214.56%；其中2026年第二季度，公司单季度主营收入4.47亿元，同比下降36.31%；单季度归母净利润-9167.96万元，同比下降1453.38%；单季度扣非净利润-9637.1万元，同比下降1038.33%；负债率24.73%，投资收益33.1万元，财务费用333.84万元，毛利率53.1%。财报数据概要请见下图:本文数据来源于振东制药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793434867861,"stockEarnings":[{"period":"1week","weight":-0.0685},{"period":"1month","weight":-0.1132},{"period":"3month","weight":-0.0629},{"period":"6month","weight":-0.1923},{"period":"1year","weight":-0.3021},{"period":"ytd","weight":-0.2048}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"44088人(较上一季度增加5.30%)","perCapita":"22493股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"99230万元","survey":" 山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是中成药、化药。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}